Your browser doesn't support javascript.
loading
[Stereotactic body radiation therapy for primary kidney cancer]. / Radiothérapie stéréotaxique des carcinomes rénaux primitifs.
Abancourt, L; Le Guévelou, J; Taillez, A; Vu, A; de Crevoisier, R; Supiot, S; Hennequin, C; Chapet, O; Blanchard, P; Mirabel, X; Lartigau, É; Pasquier, D.
Afiliação
  • Abancourt L; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France.
  • Le Guévelou J; Radiotherapy department, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France.
  • Taillez A; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France.
  • Vu A; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France.
  • de Crevoisier R; Radiotherapy department, centre régional de lutte contre le cancer Eugène-Marquis, 35042 Rennes, France.
  • Supiot S; Institut de cancérologie de l'Ouest, centre René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
  • Hennequin C; Service de cancérologie-radiothérapie, hôpital Saint-Louis, université de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France.
  • Chapet O; Département of de radiothérapie oncologie, centre hospitalier universitaire Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France; Université de Lyon, 69000 Lyon, France.
  • Blanchard P; Département de radiothérapie oncologique, Gustave-Roussy cancer campus, université Paris-Saclay, Oncostat U1018, Inserm, Villejuif, France.
  • Mirabel X; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France.
  • Lartigau É; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France; Univ. Lille & CNRS CRIStAL UMR 9189, Lille, France.
  • Pasquier D; Département universitaire de radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, Lille, France; Univ. Lille & CNRS CRIStAL UMR 9189, Lille, France. Electronic address: d-pasquier@o-lambret.fr.
Cancer Radiother ; 27(6-7): 568-572, 2023 Sep.
Article em Fr | MEDLINE | ID: mdl-37543493
The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40Gy in five fractions, 42Gy in three fractions, and 26Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Radiocirurgia / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans Idioma: Fr Revista: Cancer Radiother Assunto da revista: NEOPLASIAS / RADIOTERAPIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França País de publicação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Radiocirurgia / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Aged / Humans Idioma: Fr Revista: Cancer Radiother Assunto da revista: NEOPLASIAS / RADIOTERAPIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França País de publicação: França